Merck Reveals a Breakthrough in Biosafety Testing Efficiency with Its All-in-One Genetic Stability Assay
The Merck has reveal Aptegra™ CHO genetic stability assay, a groundbreaking all-in-one solution that enhances biosafety testing.
This innovative assay uses whole genome sequencing and bioinformatics to expedite the process from development to commercial production, efficiency and accuracy.
The FDA requires biotech companies to run multiple tests to check genetic stability. This process is expensive, takes a lot of time, and often results in data that need further analysis and explanation.
The company has enhanced its digital technology portfolio with the addition of the Aptegra™ platform.
The Aptegra™ platform makes testing easier by combining five different tests and four technologies into one. Using next-generation sequencing, it reduces testing time by 66% and cuts costs by 43%, all while meeting regulatory requirements.
The company has invested significantly over the past five years to expand its biosafety testing capabilities worldwide, with facilities in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.
In December, they introduced AIDDISON™, a groundbreaking AI-driven platform that integrates generative design with predictive synthesis planning. This innovation enables rapid identification of promising candidates and significantly mitigates the risk of late-stage failures.
They also provides the innovative Bio4C® Software Suite, which integrates data analytics, visualization, automation, and control software for GMP manufacturing.
